Table 1 Clinicodemographic characteristics of the 458 patients in the study
Characteristic | Value |
|---|---|
Female | 241 (52.62) |
Age | 60.26 ± 8.07 |
> 65 yr | 109 (23.80) |
Body mass index, kg/m2 | 24.55 ± 3.08 |
Age-adjusted Charlson Comorbidity Index | 2.00 (1.00–3.00) |
Smoking status | |
Never-smoker | 308 (67.25) |
Ex-smoker | 62 (13.54) |
Current smoker | 88 (19.21) |
Family history of malignancy | 90 (19.65) |
Surgical year | |
2015 | 124 (27.07) |
2016 | 153 (33.41) |
2017 | 181 (39.52) |
Tumor site | |
RUL | 143 (31.22) |
RML | 20 (4.37) |
RLL | 103 (22.49) |
LUL | 101 (22.05) |
LLL | 91 (19.87) |
Histopathological subtype | |
Lepidic | 25 (5.46) |
Papillary | 52 (11.35) |
Acinar | 262 (57.21) |
Micropapillary | 4 (0.87) |
Solid | 74 (16.16) |
Other | 41 (8.95) |
Number of N1 node | 6.00 (4.00–8.00) |
Number of N2 node | 9.00 (6.00–12.00) |
Number of lymph nodes examined | 15.00 (11.00–19.00) |
Spread through air space | 115 (25.11) |
pT stage | |
T1a | 37 (8.08) |
T1b | 144 (31.44) |
T1c | 135 (29.48) |
T2 | 142 (31.00) |
pN stage | |
N0 | 332 (72.49) |
N1 | 56 (12.23) |
N2 | 70 (15.28) |
pTNM stage | |
IA | 238 (51.96) |
IA1 | 34 (7.42) |
IA2 | 115 (25.11) |
IA3 | 89 (19.43) |
IB | 94 (20.52) |
IIB | 56 (12.23) |
IIIA | 70 (15.28) |
Postoperative adjuvant therapy | 249 (54.37) |
Chemotherapy | 218(47.60) |
Radiotherapy | 1(0.22) |
Targeted therapy | 30(6.55) |